Literature DB >> 16143553

Clinical and genetic aspects of craniofrontonasal syndrome: towards resolving a genetic paradox.

Peter Wieacker1, Ilse Wieland.   

Abstract

Craniofrontonasal syndrome (CFNS) is characterized by body asymmetry, midline defects, skeletal abnormalities, and dermatological abnormalities. It is a very peculiar X-linked syndrome because females are affected whereas male carriers show no or only mild abnormalities. Using a combination of positional approach and candidate gene strategy the EFNB1 gene in Xq12 was identified as the major causative gene of this condition. So far, 46 EFNB1 mutations have been detected in CFNS patients. The majority of the mutations lead to premature termination codons. Because the encoded protein ephrin-B1 is involved in migration of neural crest cells we propose that CFNS is a novel type of neurocrestopathy. The absent or mild phenotype in male carriers may be explained by the promiscuity of the ephrin ligand/receptor system. The more severe manifestation in females may be explained by cellular interference that is caused by the combination of ephrin ligand/receptor promiscuity and the consequences of random X inactivation in distinct cellular compartments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143553     DOI: 10.1016/j.ymgme.2005.07.017

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  25 in total

1.  Craniosynostosis.

Authors:  David Johnson; Andrew O M Wilkie
Journal:  Eur J Hum Genet       Date:  2011-01-19       Impact factor: 4.246

2.  The origin of EFNB1 mutations in craniofrontonasal syndrome: frequent somatic mosaicism and explanation of the paucity of carrier males.

Authors:  Stephen R F Twigg; Kazuya Matsumoto; Alexa M J Kidd; Anne Goriely; Indira B Taylor; Richard B Fisher; A Jeannette M Hoogeboom; Irene M J Mathijssen; M Teresa Lourenco; Jenny E V Morton; Elizabeth Sweeney; Louise C Wilson; Han G Brunner; John B Mulliken; Steven A Wall; Andrew O M Wilkie
Journal:  Am J Hum Genet       Date:  2006-04-28       Impact factor: 11.025

Review 3.  Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes.

Authors:  Timothy J Edwards; Elliott H Sherr; A James Barkovich; Linda J Richards
Journal:  Brain       Date:  2014-01-28       Impact factor: 13.501

4.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

5.  Four novel mutations in EFNB1 in Indian patients with craniofrontonasal syndrome.

Authors:  Antonia Howaldt; Sheela Nampoothiri; Dhanya Yesodharan; Suhas Udayakumaran; Pramod Subash; Uwe Kornak
Journal:  J Hum Genet       Date:  2019-07-08       Impact factor: 3.172

6.  Ephrin-B1 forward signaling regulates craniofacial morphogenesis by controlling cell proliferation across Eph-ephrin boundaries.

Authors:  Jeffrey O Bush; Philippe Soriano
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

7.  Craniofrontonasal dysplasia: hypertelorism correction in late presenting patients.

Authors:  Cassio Eduardo Raposo-Amaral; Gabriel Resende; Rafael Denadai; Enrico Ghizoni; Cesar Augusto Raposo-Amaral
Journal:  Childs Nerv Syst       Date:  2021-04-16       Impact factor: 1.475

8.  Phenotypes of craniofrontonasal syndrome in patients with a pathogenic mutation in EFNB1.

Authors:  M E P van den Elzen; S R F Twigg; J A C Goos; A J M Hoogeboom; A M W van den Ouweland; A O M Wilkie; I M J Mathijssen
Journal:  Eur J Hum Genet       Date:  2013-11-27       Impact factor: 4.246

9.  A subset of signal transduction pathways is required for hippocampal growth cone collapse induced by ephrin-A5.

Authors:  Xin Yue; Cheryl Dreyfus; Tony Ah-Ng Kong; Renping Zhou
Journal:  Dev Neurobiol       Date:  2008-09-01       Impact factor: 3.964

Review 10.  Genetic aspects of human congenital diaphragmatic hernia.

Authors:  B R Pober
Journal:  Clin Genet       Date:  2008-05-28       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.